During the last decade, numerous strategies against TGF-β signaling have been used in preclinical or clinical applications, especially in end-stage cancer, including anti-ligand antisense oligonucleotides, antibodies that target ligands or receptors, and drugs against TGF-β receptor kinases (reviewed in [40,96]). Here, TGFB1 is linked to cancer.